Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seol, JG | - |
dc.contributor.author | Park, WH | - |
dc.contributor.author | Kim, ES | - |
dc.contributor.author | Jung, CW | - |
dc.contributor.author | Hyun, JM | - |
dc.contributor.author | Kim, BK | - |
dc.contributor.author | Lee, YY | - |
dc.date.accessioned | 2021-06-18T14:44:28Z | - |
dc.date.available | 2021-06-18T14:44:28Z | - |
dc.date.issued | 1999-11 | - |
dc.identifier.issn | 0006-291X | - |
dc.identifier.issn | 1090-2104 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/47417 | - |
dc.description.abstract | Arsenic trioxide (As2O3) has been shown to inhibit the proliferation of hematologic malignant cells. However, little is known about the effect of As2O3 on solid tumor. In this study, we investigated the antitumoral effect of As2O3 on head and neck cancer cell lines in vitro. Treatment of As2O3 inhibited the proliferation of all of 4 cell lines examined in a dose-dependent manner. To address the mechanism of antitumoral effect of As2O3, cell cycle analysis was attempted in As2O3-most sensitive PCI-1 cells. Treatment of As2O3 (2 mu M) induced efficiently G2/M arrest in PCI-1 cells following 3 days of exposure. During the G2/M arrest, cyclin-dependent kinase inhibitor, p21, was increased in a time-dependent manner. Analysis of cell cycle regulatory proteins demonstrated that As2O3 (2 mu M) did not change the steady-state levels of CDK2, CDK4, CDK6, cyclin D1, cyclin E and cyclin A, but decreased the protein levels of cdc2 and cyclin B1. Furthermore, treatment of As2O3 markedly enhanced the binding of p21 with cdc2, and the activity of cdc2 kinase was decreased in a time-dependent manner. These results suggest that As2O3 inhibits the proliferation of head and neck cancer cells via G2/M arrest in association with the induction of p21 and the reduction of cdc2 kinase activity. (C) 1999 Academic Press. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ACADEMIC PRESS INC | - |
dc.title | Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1 | - |
dc.type | Article | - |
dc.identifier.doi | 10.1006/bbrc.1999.1697 | - |
dc.identifier.bibliographicCitation | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, v.265, no.2, pp 400 - 404 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000083899100024 | - |
dc.identifier.scopusid | 2-s2.0-0033584827 | - |
dc.citation.endPage | 404 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 400 | - |
dc.citation.title | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | - |
dc.citation.volume | 265 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | ACUTE PROMYELOCYTIC LEUKEMIA | - |
dc.subject.keywordPlus | POTENTIAL MEDIATOR | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | RAR-ALPHA | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | KINASES | - |
dc.subject.keywordPlus | PML | - |
dc.subject.keywordPlus | TRANSCRIPTION | - |
dc.subject.keywordPlus | MELARSOPROL | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.